U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C15H21NO2
Molecular Weight 247.3327
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of MEPERIDINE

SMILES

CCOC(=O)C1(CCN(C)CC1)C2=CC=CC=C2

InChI

InChIKey=XADCESSVHJOZHK-UHFFFAOYSA-N
InChI=1S/C15H21NO2/c1-3-18-14(17)15(9-11-16(2)12-10-15)13-7-5-4-6-8-13/h4-8H,3,9-12H2,1-2H3

HIDE SMILES / InChI
Molecular Formula C15H21NO2
Molecular Weight 247.3327
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including: http://www.pbm.va.gov/clinicalguidance/criteriaforuse/MeperidineCriteriaforUse.pdf | https://www.drugs.com/pro/meperidine.html

Pethidine, also known as meperidine and Demerol, a narcotic analgesic that can be used for the relief of most types of moderate to severe pain, including postoperative pain and the pain of labor. Meperidine is an opioid agonist with multiple actions qualitatively similar to those of morphine. Most common adverse reactions were lightheadedness, dizziness, sedation, nausea, vomiting, and sweating. Pethidine has serious interactions that can be dangerous with monoamine oxidase inhibitors (e.g., furazolidone, isocarboxazid, moclobemide, phenelzine, procarbazine, selegiline, tranylcypromine). Pethidine can interact with muscle relaxants, some antidepressants, benzodiazepines, and ethanol.

CNS Activity

Originator

Approval Year

1942
36
Targets

Targets

Primary TargetPharmacologyConditionPotency
Agonist
2662
 450.1 nM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8360
DEMEROL

Approved Use

For the relief of moderate to severe pain. For preoperative medication. For support of anesthesia. For obstetrical analgesia.

Launch Date

-8.5656961E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
196 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/2891328/
30 mg single, intravenous
dose: 30 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
MEPERIDINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
19.6 μg × min/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/2891328/
30 mg single, intravenous
dose: 30 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
MEPERIDINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
124 min
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/2891328/
30 mg single, intravenous
dose: 30 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
MEPERIDINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
10 g single, oral
Overdose
Dose: 10 g
Route: oral
Route: single
Dose: 10 g
Sources:
https://pubmed.ncbi.nlm.nih.gov/17364646
unknown, 17 years
Health Status: unknown
Age Group: 17 years
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/17364646
Other AEs: Myoclonus, Hyperreflexia...
Other AEs:
Myoclonus (1 patient)
Hyperreflexia (1 patient)
Respiratory depression (1 patient)
Hypotension (1 patient)
Tremor (1 patient)
Sources:
https://pubmed.ncbi.nlm.nih.gov/17364646
50 mg single, intrathecal
Dose: 50 mg
Route: intrathecal
Route: single
Dose: 50 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/7923521
unknown, 24 - 81 years
Health Status: unknown
Age Group: 24 - 81 years
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/7923521
Other AEs: Respiratory depression...
Other AEs:
Respiratory depression (2 patients)
Sources:
https://pubmed.ncbi.nlm.nih.gov/7923521
1000 mg 1 times / day multiple, intramuscular
Highest studied dose
Dose: 1000 mg, 1 times / day
Route: intramuscular
Route: multiple
Dose: 1000 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/3941530/
unhealthy, 37 years
n = 1
Health Status: unhealthy
Condition: pain
Age Group: 37 years
Sex: M
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/3941530/
Disc. AE: Muscle twitching, Tremor...
AEs leading to
discontinuation/dose reduction:
Muscle twitching (1 patient)
Tremor (1 patient)
Sources:
https://pubmed.ncbi.nlm.nih.gov/3941530/
600 mg 1 times / day multiple, intravenous
Highest studied dose
Dose: 600 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 600 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/11772223
unknown, 44 years
n = 7
Health Status: unknown
Age Group: 44 years
Sex: M+F
Population Size: 7
Sources:
https://pubmed.ncbi.nlm.nih.gov/11772223
Other AEs: Jitteriness, Hallucinations...
Other AEs:
Jitteriness (3 patients)
Hallucinations (3 patients)
Seizures (3 patients)
Sources:
https://pubmed.ncbi.nlm.nih.gov/11772223
50 mg 6 times / day multiple, intramuscular
Recommended
Dose: 50 mg, 6 times / day
Route: intramuscular
Route: multiple
Dose: 50 mg, 6 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021171s032lbl.pdf
pregnant, adult
Health Status: pregnant
Age Group: adult
Sex: F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021171s032lbl.pdf
Other AEs: Withdrawal syndrome neonatal...
Other AEs:
Withdrawal syndrome neonatal
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021171s032lbl.pdf
50 mg 6 times / day multiple, oral
Recommended
Dose: 50 mg, 6 times / day
Route: oral
Route: multiple
Dose: 50 mg, 6 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/005010s059lbl.pdf
pregnant, adult
Health Status: pregnant
Condition: pain
Age Group: adult
Sex: F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/005010s059lbl.pdf
Other AEs: Withdrawal syndrome neonatal...
Other AEs:
Withdrawal syndrome neonatal
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/005010s059lbl.pdf
50 mg 6 times / day multiple, subcutaneous
Recommended
Dose: 50 mg, 6 times / day
Route: subcutaneous
Route: multiple
Dose: 50 mg, 6 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021171s032lbl.pdf
pregnant, adult
Health Status: pregnant
Age Group: adult
Sex: F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021171s032lbl.pdf
Other AEs: Withdrawal syndrome neonatal...
Other AEs:
Withdrawal syndrome neonatal
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021171s032lbl.pdf
50 mg 6 times / day multiple, intramuscular
Recommended
Dose: 50 mg, 6 times / day
Route: intramuscular
Route: multiple
Dose: 50 mg, 6 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021171s032lbl.pdf
unhealthy, adult
Health Status: unhealthy
Condition: pain
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021171s032lbl.pdf
Other AEs: Addiction, Respiratory depression...
Other AEs:
Addiction
Respiratory depression (serious|grade 5)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021171s032lbl.pdf
50 mg 6 times / day multiple, oral
Recommended
Dose: 50 mg, 6 times / day
Route: oral
Route: multiple
Dose: 50 mg, 6 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/005010s059lbl.pdf
unhealthy, adult
Health Status: unhealthy
Condition: pain
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/005010s059lbl.pdf
Other AEs: Addiction, Respiratory depression...
Other AEs:
Addiction
Respiratory depression (serious|grade 5)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/005010s059lbl.pdf
50 mg 6 times / day multiple, subcutaneous
Recommended
Dose: 50 mg, 6 times / day
Route: subcutaneous
Route: multiple
Dose: 50 mg, 6 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021171s032lbl.pdf
unhealthy, adult
Health Status: unhealthy
Condition: pain
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021171s032lbl.pdf
Other AEs: Addiction, Respiratory depression...
Other AEs:
Addiction
Respiratory depression (serious|grade 5)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021171s032lbl.pdf
10 mg/mL multiple, intravenous
Recommended
Dose: 10 mg/mL
Route: intravenous
Route: multiple
Dose: 10 mg/mL
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021171s032lbl.pdf
pregnant, adult
Health Status: pregnant
Age Group: adult
Sex: F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021171s032lbl.pdf
Other AEs: Withdrawal syndrome neonatal...
Other AEs:
Withdrawal syndrome neonatal
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021171s032lbl.pdf
10 mg/mL multiple, intravenous
Recommended
Dose: 10 mg/mL
Route: intravenous
Route: multiple
Dose: 10 mg/mL
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021171s032lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021171s032lbl.pdf
Other AEs: Addiction, Respiratory depression...
Other AEs:
Addiction
Respiratory depression (serious|grade 5)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021171s032lbl.pdf
AEs

AEs

AESignificanceDosePopulation
Hyperreflexia 1 patient
10 g single, oral
Overdose
Dose: 10 g
Route: oral
Route: single
Dose: 10 g
Sources:
https://pubmed.ncbi.nlm.nih.gov/17364646
unknown, 17 years
Health Status: unknown
Age Group: 17 years
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/17364646
Hypotension 1 patient
10 g single, oral
Overdose
Dose: 10 g
Route: oral
Route: single
Dose: 10 g
Sources:
https://pubmed.ncbi.nlm.nih.gov/17364646
unknown, 17 years
Health Status: unknown
Age Group: 17 years
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/17364646
Myoclonus 1 patient
10 g single, oral
Overdose
Dose: 10 g
Route: oral
Route: single
Dose: 10 g
Sources:
https://pubmed.ncbi.nlm.nih.gov/17364646
unknown, 17 years
Health Status: unknown
Age Group: 17 years
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/17364646
Respiratory depression 1 patient
10 g single, oral
Overdose
Dose: 10 g
Route: oral
Route: single
Dose: 10 g
Sources:
https://pubmed.ncbi.nlm.nih.gov/17364646
unknown, 17 years
Health Status: unknown
Age Group: 17 years
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/17364646
Tremor 1 patient
10 g single, oral
Overdose
Dose: 10 g
Route: oral
Route: single
Dose: 10 g
Sources:
https://pubmed.ncbi.nlm.nih.gov/17364646
unknown, 17 years
Health Status: unknown
Age Group: 17 years
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/17364646
Respiratory depression 2 patients
50 mg single, intrathecal
Dose: 50 mg
Route: intrathecal
Route: single
Dose: 50 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/7923521
unknown, 24 - 81 years
Health Status: unknown
Age Group: 24 - 81 years
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/7923521
Muscle twitching 1 patient
Disc. AE
1000 mg 1 times / day multiple, intramuscular
Highest studied dose
Dose: 1000 mg, 1 times / day
Route: intramuscular
Route: multiple
Dose: 1000 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/3941530/
unhealthy, 37 years
n = 1
Health Status: unhealthy
Condition: pain
Age Group: 37 years
Sex: M
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/3941530/
Tremor 1 patient
Disc. AE
1000 mg 1 times / day multiple, intramuscular
Highest studied dose
Dose: 1000 mg, 1 times / day
Route: intramuscular
Route: multiple
Dose: 1000 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/3941530/
unhealthy, 37 years
n = 1
Health Status: unhealthy
Condition: pain
Age Group: 37 years
Sex: M
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/3941530/
Hallucinations 3 patients
600 mg 1 times / day multiple, intravenous
Highest studied dose
Dose: 600 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 600 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/11772223
unknown, 44 years
n = 7
Health Status: unknown
Age Group: 44 years
Sex: M+F
Population Size: 7
Sources:
https://pubmed.ncbi.nlm.nih.gov/11772223
Jitteriness 3 patients
600 mg 1 times / day multiple, intravenous
Highest studied dose
Dose: 600 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 600 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/11772223
unknown, 44 years
n = 7
Health Status: unknown
Age Group: 44 years
Sex: M+F
Population Size: 7
Sources:
https://pubmed.ncbi.nlm.nih.gov/11772223
Seizures 3 patients
600 mg 1 times / day multiple, intravenous
Highest studied dose
Dose: 600 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 600 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/11772223
unknown, 44 years
n = 7
Health Status: unknown
Age Group: 44 years
Sex: M+F
Population Size: 7
Sources:
https://pubmed.ncbi.nlm.nih.gov/11772223
Withdrawal syndrome neonatal
50 mg 6 times / day multiple, intramuscular
Recommended
Dose: 50 mg, 6 times / day
Route: intramuscular
Route: multiple
Dose: 50 mg, 6 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021171s032lbl.pdf
pregnant, adult
Health Status: pregnant
Age Group: adult
Sex: F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021171s032lbl.pdf
Withdrawal syndrome neonatal
50 mg 6 times / day multiple, oral
Recommended
Dose: 50 mg, 6 times / day
Route: oral
Route: multiple
Dose: 50 mg, 6 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/005010s059lbl.pdf
pregnant, adult
Health Status: pregnant
Condition: pain
Age Group: adult
Sex: F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/005010s059lbl.pdf
Withdrawal syndrome neonatal
50 mg 6 times / day multiple, subcutaneous
Recommended
Dose: 50 mg, 6 times / day
Route: subcutaneous
Route: multiple
Dose: 50 mg, 6 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021171s032lbl.pdf
pregnant, adult
Health Status: pregnant
Age Group: adult
Sex: F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021171s032lbl.pdf
Addiction
50 mg 6 times / day multiple, intramuscular
Recommended
Dose: 50 mg, 6 times / day
Route: intramuscular
Route: multiple
Dose: 50 mg, 6 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021171s032lbl.pdf
unhealthy, adult
Health Status: unhealthy
Condition: pain
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021171s032lbl.pdf
Respiratory depression serious|grade 5
50 mg 6 times / day multiple, intramuscular
Recommended
Dose: 50 mg, 6 times / day
Route: intramuscular
Route: multiple
Dose: 50 mg, 6 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021171s032lbl.pdf
unhealthy, adult
Health Status: unhealthy
Condition: pain
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021171s032lbl.pdf
Addiction
50 mg 6 times / day multiple, oral
Recommended
Dose: 50 mg, 6 times / day
Route: oral
Route: multiple
Dose: 50 mg, 6 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/005010s059lbl.pdf
unhealthy, adult
Health Status: unhealthy
Condition: pain
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/005010s059lbl.pdf
Respiratory depression serious|grade 5
50 mg 6 times / day multiple, oral
Recommended
Dose: 50 mg, 6 times / day
Route: oral
Route: multiple
Dose: 50 mg, 6 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/005010s059lbl.pdf
unhealthy, adult
Health Status: unhealthy
Condition: pain
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/005010s059lbl.pdf
Addiction
50 mg 6 times / day multiple, subcutaneous
Recommended
Dose: 50 mg, 6 times / day
Route: subcutaneous
Route: multiple
Dose: 50 mg, 6 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021171s032lbl.pdf
unhealthy, adult
Health Status: unhealthy
Condition: pain
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021171s032lbl.pdf
Respiratory depression serious|grade 5
50 mg 6 times / day multiple, subcutaneous
Recommended
Dose: 50 mg, 6 times / day
Route: subcutaneous
Route: multiple
Dose: 50 mg, 6 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021171s032lbl.pdf
unhealthy, adult
Health Status: unhealthy
Condition: pain
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021171s032lbl.pdf
Withdrawal syndrome neonatal
10 mg/mL multiple, intravenous
Recommended
Dose: 10 mg/mL
Route: intravenous
Route: multiple
Dose: 10 mg/mL
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021171s032lbl.pdf
pregnant, adult
Health Status: pregnant
Age Group: adult
Sex: F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021171s032lbl.pdf
Addiction
10 mg/mL multiple, intravenous
Recommended
Dose: 10 mg/mL
Route: intravenous
Route: multiple
Dose: 10 mg/mL
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021171s032lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021171s032lbl.pdf
Respiratory depression serious|grade 5
10 mg/mL multiple, intravenous
Recommended
Dose: 10 mg/mL
Route: intravenous
Route: multiple
Dose: 10 mg/mL
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021171s032lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021171s032lbl.pdf
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
substrate
1709
inhibitor
1599

OverviewOther

Other InhibitorOther SubstrateOther Inducer
CYP2B6
660

CYP2C19
985
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
CYP2C19
985
 yes
CYP2B6
660
 yes
likely (co-administration study)
Comment: The concomitant use of DEMEROL Injection and CYP3A4 or CYP2B6 inhibitors can increase the plasma concentration of meperidine, resulting in increased or prolonged opioid effects; The concomitant use of DEMEROL Injection and CYP3A4 inducers, or CYP2B6 inducers can decrease the plasma concentration of meperidine
Page: 20.0
CYP3A4
1709
 yes
likely (co-administration study)
Comment: The concomitant use of DEMEROL Injection and CYP3A4 or CYP2B6 inhibitors can increase the plasma concentration of meperidine, resulting in increased or prolonged opioid effects; The concomitant use of DEMEROL Injection and CYP3A4 inducers, or CYP2B6 inducers can decrease the plasma concentration of meperidine
Page: 20.0
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
hERG
1632
Sourcing

Sourcing

Vendor/AggregatorIDURL
3B Scientific (Wuhan) Corp
3B2-3283
http://www.3bsc.com/index/pro_info.php?id=76334
Ambinter
Amb17939801
http://www.ambinter.com/reference/17939801
Aurora Fine Chemicals LLC
A17.902.511
http://online.aurorafinechemicals.com/info?ID=A17.902.511
ChemMol
99111237
http://www.chemmol.com/chemmol/99111237.html
Clearsynth
CS-ED-00291
https://www.clearsynth.com/en/CSED00291.html
Clearsynth
CS-R-00538
https://www.clearsynth.com/en/CSR00538.html
Debye Scientific
DB-053051
http://www.debyesci.com/cas_57-42-1.html
LGC Standards
LGCAMP0315.11-01
https://www.lgcstandards.com/US/en/p/LGCAMP0315.11-01
LGC Standards
LGCAMP0315.11-02
https://www.lgcstandards.com/US/en/p/LGCAMP0315.11-02
Sigma-Aldrich
M-035_CERILLIAN
https://www.sigmaaldrich.com/catalog/product/cerillian/m035?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich
610593_SIAL
https://www.sigmaaldrich.com/catalog/product/sial/610593?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sinfoo Biotech
S012160
http://www.sinfoobiotech.com/product/1015558
Smolecule
S577894
https://www.smolecule.com/products/s577894
PubMed

PubMed

TitleDatePubMed
[Meperidine (pethidine) outdated as analgesic in acute pancreatitis].
2000 Apr 1
Successful treatment of normeperidine neurotoxicity by hemodialysis.
2000 Jan
Pethidine reverses morphine-induced delirium.
2000 Jun
Urticaria induced by meperidine allergy.
2000 Mar
Sedation and analgesia for transvaginal oocyte retrieval: an audit resulting in a change of clinical practice.
2001
Morphine, pethidine and buprenorphine disposition in the cat.
2001 Dec
[Comparison of vaginal misoprostol and oxytocin for labor induction in post-term pregnancy].
2001 Dec
A randomized comparison of low-dose ketamine and lignocaine infiltration with ketamine-diazepam anaesthesia for post partum tubal ligation in Vanuatu.
2001 Feb
Preoperative rectal diclofenac versus paracetamol for tonsillectomy: effects on pain and blood loss.
2001 Jan
Randomized trial of needlescopic versus laparoscopic cholecystectomy.
2001 Jan
Remifentanil versus meperidine for monitored anesthesia care: a comparison study in older patients undergoing ambulatory colonoscopy.
2001 Jan
Using evidence from different sources: an example using paracetamol 1000 mg plus codeine 60 mg.
2001 Jan 10
Opiate-sensitivity: clinical characteristics and the role of skin prick testing.
2001 Jul
Use of a new finger-mounted device to compare mechanical nociceptive thresholds in cats given pethidine or no medication after castration.
2001 Jun
Maternal analgesia during labor disturbs newborn behavior: effects on breastfeeding, temperature, and crying.
2001 Mar
Efficacy and safety of repeated postoperative administration of intramuscular diclofenac sodium in the treatment of post-cesarean section pain: a double-blind study.
2001 Mar-Apr
Upper and mid-ureteric stones: a prospective unrandomized comparison of retroperitoneoscopic and open ureterolithotomy.
2001 Nov
Patient-controlled pethidine after major upper abdominal surgery: comparison of the epidural and intravenous routes.
2001 Nov
Clinical experience and results of ESWL treatment for 3,093 urinary calculi with the Storz Modulith SL 20 lithotripter at the Singapore general hospital.
2002
Use of opioid analgesics in a patient with chronic abdominal pain.
2002 Apr
Primary thoracoscopic evaluation of pleural effusion with local anesthesia: an alternative approach.
2002 Apr-Jun
Pulmonary function in infants exposed to pethidine.
2002 Aug
Selegiline: a second look. Six years later: too risky in Parkinson's disease.
2002 Aug
Upper gastrointestinal endoscopic ultrasound and its impact on patient management: 1990-2000.
2002 Aug
Nasal administration of opioids for pain management in adults.
2002 Aug
Noninvasive anesthesia, analgesia and radiation-free extracorporeal shock wave lithotripsy for stones in the most distal ureter: experience with 165 patients.
2002 Aug
Intraperitoneal pethidine versus intramuscular pethidine for the relief of pain after laparoscopic cholecystectomy: randomized trial.
2002 Dec
Vitamin K and childhood cancer: analysis of individual patient data from six case-control studies.
2002 Jan 7
Mini cholecystectomy now a day stay surgery: anaesthetic management with multi modal analgesia.
2002 Jul
Double-blind, randomized trial comparing Harmonic Scalpel hemorrhoidectomy, bipolar scissors hemorrhoidectomy, and scissors excision: ligation technique.
2002 Jun
Liquid-phase microextraction of protein-bound drugs under non-equilibrium conditions.
2002 May
Parenteral opioids for labor pain relief: a systematic review.
2002 May
Anxiolytic premedication reduces preoperative anxiety and pain during oocyte retrieval. A randomized double-blinded placebo-controlled trial.
2002 May
Next generation of everyday analgesics.
2002 May-Jun
Comparison of intravenous ketorolac and meperidine in the treatment of biliary colic.
2002 Oct
[Long-memory of labor pain].
2002 Oct 14
Characterisation of silent and active genes for a variable large protein of Borrelia recurrentis.
2002 Oct 14
Two in one: patient-controlled epidural analgesia (PCEA) to prevent erection and control pain in adult hypospadias-surgery patients.
2002 Sep
Can ketamine potentiate the analgesic effect of epidural morphine, preincisional or postincisional administration?
2002 Sep
Patents

Patents

20010004644
50
JP2000501709A
75
JP2003522127A
12
JP2004527491A
36
JP2005530798A
42
JP2009526755A
442
JP4642467B2
32
JP4790415B2
14
JP4800219B2
65

Sample Use Guides

In Vivo Use Guide
Oral: 50 to 100 mg every 4 hours as needed. IV,IM,subcutaneously: 25 to 100 mg every 4 hours as needed. Continuous IV: 15 to 35 mg/hr.
Route of Administration: Other
In Vitro Use Guide
Pethidine's stimulant action on the 22-day pregnant rat isolated uterus does not involve receptors sensitive to methysergide and is unlikely to involve the synthesis and release of endogenous prostaglandins. Maximal stimulant response occurred with 40 ug/ml.
Substance Class Chemical
Created
by admin
on Thu Jul 06 23:23:24 UTC 2023
Edited
by admin
on Thu Jul 06 23:23:24 UTC 2023
Record UNII
9E338QE28F
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
MEPERIDINE
HSDB   MI   VANDF  
Common Name English
PETHIDINE
INN   WHO-DD  
INN  
Official Name English
IDS-NP-001
Code English
MEPERIDINE [MI]
Common Name English
RENAUDIN
Common Name English
PETHANOL
Common Name English
4-PIPERIDINECARBOXYLIC ACID, 1-METHYL-4-PHENYL-, ETHYL ESTER
Common Name English
ETHYL 1-METHYL-4-PHENYLISONIPECOTATE
Systematic Name English
ISONIPECAINE
Common Name English
PETHIDINETER
Common Name English
ISONIPECOTIC ACID, 1-METHYL-4-PHENYL-, ETHYL ESTER
Systematic Name English
1-METHYL-4-PHENYLPIPERIDINE-4-CARBOXYLIC ACID ETHYL ESTER
Systematic Name English
MEPERIDINE [HSDB]
Common Name English
MEPERIDINE [VANDF]
Common Name English
MEPERIDOL
Common Name English
PETHIDINE DBL
Brand Name English
ETHYL 1-METHYL-4-PHENYLPIPERIDINE-4-CARBOXYLATE
Systematic Name English
Pethidine [WHO-DD]
Common Name English
pethidine [INN]
Common Name English
Classification Tree Code System Code
WHO-VATC QN02AG03
Created by admin on Thu Jul 06 23:23:25 UTC 2023 , Edited by admin on Thu Jul 06 23:23:25 UTC 2023
NCI_THESAURUS C67413
Created by admin on Thu Jul 06 23:23:25 UTC 2023 , Edited by admin on Thu Jul 06 23:23:25 UTC 2023
WHO-ATC N02AB72
Created by admin on Thu Jul 06 23:23:25 UTC 2023 , Edited by admin on Thu Jul 06 23:23:25 UTC 2023
LIVERTOX NBK548764
Created by admin on Thu Jul 06 23:23:25 UTC 2023 , Edited by admin on Thu Jul 06 23:23:25 UTC 2023
NDF-RT N0000175690
Created by admin on Thu Jul 06 23:23:25 UTC 2023 , Edited by admin on Thu Jul 06 23:23:25 UTC 2023
DEA NO. 9230
Created by admin on Thu Jul 06 23:23:25 UTC 2023 , Edited by admin on Thu Jul 06 23:23:25 UTC 2023
WHO-ATC N02AB52
Created by admin on Thu Jul 06 23:23:25 UTC 2023 , Edited by admin on Thu Jul 06 23:23:25 UTC 2023
NDF-RT N0000175684
Created by admin on Thu Jul 06 23:23:25 UTC 2023 , Edited by admin on Thu Jul 06 23:23:25 UTC 2023
WHO-VATC QN02AB72
Created by admin on Thu Jul 06 23:23:25 UTC 2023 , Edited by admin on Thu Jul 06 23:23:25 UTC 2023
WHO-VATC QN02AB02
Created by admin on Thu Jul 06 23:23:25 UTC 2023 , Edited by admin on Thu Jul 06 23:23:25 UTC 2023
WHO-ATC N02AB02
Created by admin on Thu Jul 06 23:23:25 UTC 2023 , Edited by admin on Thu Jul 06 23:23:25 UTC 2023
WHO-VATC QN02AB52
Created by admin on Thu Jul 06 23:23:25 UTC 2023 , Edited by admin on Thu Jul 06 23:23:25 UTC 2023
WHO-ATC N02AG03
Created by admin on Thu Jul 06 23:23:25 UTC 2023 , Edited by admin on Thu Jul 06 23:23:25 UTC 2023
Code System Code Type Description
EPA CompTox
DTXSID9023253
Created by admin on Thu Jul 06 23:23:25 UTC 2023 , Edited by admin on Thu Jul 06 23:23:25 UTC 2023
PRIMARY
RXCUI
6754
Created by admin on Thu Jul 06 23:23:25 UTC 2023 , Edited by admin on Thu Jul 06 23:23:25 UTC 2023
PRIMARY RxNorm
CAS
57-42-1
Created by admin on Thu Jul 06 23:23:25 UTC 2023 , Edited by admin on Thu Jul 06 23:23:25 UTC 2023
PRIMARY
SMS_ID
100000082223
Created by admin on Thu Jul 06 23:23:25 UTC 2023 , Edited by admin on Thu Jul 06 23:23:25 UTC 2023
PRIMARY
IUPHAR
7221
Created by admin on Thu Jul 06 23:23:25 UTC 2023 , Edited by admin on Thu Jul 06 23:23:25 UTC 2023
PRIMARY
INN
411
Created by admin on Thu Jul 06 23:23:25 UTC 2023 , Edited by admin on Thu Jul 06 23:23:25 UTC 2023
PRIMARY
ECHA (EC/EINECS)
200-329-1
Created by admin on Thu Jul 06 23:23:25 UTC 2023 , Edited by admin on Thu Jul 06 23:23:25 UTC 2023
PRIMARY
WIKIPEDIA
PETHIDINE
Created by admin on Thu Jul 06 23:23:25 UTC 2023 , Edited by admin on Thu Jul 06 23:23:25 UTC 2023
PRIMARY
DRUG BANK
DB00454
Created by admin on Thu Jul 06 23:23:25 UTC 2023 , Edited by admin on Thu Jul 06 23:23:25 UTC 2023
PRIMARY
LACTMED
Meperidine
Created by admin on Thu Jul 06 23:23:25 UTC 2023 , Edited by admin on Thu Jul 06 23:23:25 UTC 2023
PRIMARY
PUBCHEM
4058
Created by admin on Thu Jul 06 23:23:25 UTC 2023 , Edited by admin on Thu Jul 06 23:23:25 UTC 2023
PRIMARY
ChEMBL
CHEMBL607
Created by admin on Thu Jul 06 23:23:25 UTC 2023 , Edited by admin on Thu Jul 06 23:23:25 UTC 2023
PRIMARY
MESH
D008614
Created by admin on Thu Jul 06 23:23:25 UTC 2023 , Edited by admin on Thu Jul 06 23:23:25 UTC 2023
PRIMARY
NCI_THESAURUS
C71632
Created by admin on Thu Jul 06 23:23:25 UTC 2023 , Edited by admin on Thu Jul 06 23:23:25 UTC 2023
PRIMARY
DAILYMED
9E338QE28F
Created by admin on Thu Jul 06 23:23:25 UTC 2023 , Edited by admin on Thu Jul 06 23:23:25 UTC 2023
PRIMARY
FDA UNII
9E338QE28F
Created by admin on Thu Jul 06 23:23:25 UTC 2023 , Edited by admin on Thu Jul 06 23:23:25 UTC 2023
PRIMARY
HSDB
3116
Created by admin on Thu Jul 06 23:23:25 UTC 2023 , Edited by admin on Thu Jul 06 23:23:25 UTC 2023
PRIMARY
EVMPD
SUB09738MIG
Created by admin on Thu Jul 06 23:23:25 UTC 2023 , Edited by admin on Thu Jul 06 23:23:25 UTC 2023
PRIMARY
MERCK INDEX
M7186
Created by admin on Thu Jul 06 23:23:25 UTC 2023 , Edited by admin on Thu Jul 06 23:23:25 UTC 2023
PRIMARY Merck Index
DRUG CENTRAL
1690
Created by admin on Thu Jul 06 23:23:25 UTC 2023 , Edited by admin on Thu Jul 06 23:23:25 UTC 2023
PRIMARY
CHEBI
6754
Created by admin on Thu Jul 06 23:23:25 UTC 2023 , Edited by admin on Thu Jul 06 23:23:25 UTC 2023
PRIMARY
Related Record Type Details
CYTOCHROME P450 3A4
METABOLIC ENZYME -> SUBSTRATE
MAJOR
Structure of MEPERIDINE HYDROCHLORIDE
SALT/SOLVATE -> PARENT
APPROXIMATE PURE ANHYDROUS DRUG CONTENT (IN PERCENT)
CYTOCHROME P450 2C19
METABOLIC ENZYME -> SUBSTRATE
MINOR
PLASMA PROTEIN FRACTION (HUMAN)
BINDER->LIGAND
CYTOCHROME P450 2B6
METABOLIC ENZYME -> SUBSTRATE
MAJOR
Structure of 4-Fluoropethidine
DERIVATIVE -> PARENT
Related Record Type Details
Structure of MEPERIDINE
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC Elimination
PHARMACOKINETIC
Elimination
PHARMACOKINETIC
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966